SD220729-017 page 1 of 1

PharmLabs San Diego Certificate of Analysis

Sample Canna Kings Delta 8 Cookies



Delta9 THC UI THCa ND Total THC (THC + THCa) UI Delta8 THC 3.21%

Sample ID SD220729-017 (50079)		Matrix Edible (Other Cannabis Good)
Tested for Canna Kings		
Sampled -	Received Jul 28, 2022	Reported Aug 05, 2022
Analyses executed CANX		Unit Mass (g) 46.88

Laboratory note: The estimated concentration of the unknown peak in the sample is 0.05% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)d8-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC, (+)d8-THC is a different compound from the main (-)d8-THC contabinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC and d9-THC and d9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)d8-THC with the majority, if not all, of the concentration being (+)d8-THC. Total (+/-) D8 concentration is estimated to be 0.05%.

CANX - Cannabinoids Analysis Analyzed Aug 05, 2022 | Instrument HPLC-VWD | Method SOP-001 The expanded Uncertainty of the Cannabinoid analysis is approximately *3*.806% at the 95% Confidence Level

11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV) 0.013 0.041 Cannabidiorcin (CBDO) 0.002 0.007 Abnormal Cannabidiorcin (α-CBDO) 0.01 0.013 (+/-)-98-hydrocannibinol (9b-HHC) 0.012 0.036 11-Hydroxy-Δ8-Tetrahydrocannibinol (9b-HHC) 0.007 0.021 Cannabidiolic Acid (CBDA) 0.001 0.16 Cannabigerol Acid (CBGA) 0.001 0.16 Cannabigerol (CBG) 0.001 0.16 Cannabidiol (CBD) 0.001 0.16 Cannabidiol (CBD) 0.001 0.16 Cannabidiol (CBD) 0.001 0.16 Cannabidiol (CBD) 0.001 0.016 Cannabidiol (CBD) 0.001 0.16	NT NT NT ND ND ND ND ND ND NT	NT NT NT ND ND ND ND	NT NT NT NT ND ND ND	
Abnormal Cannabidiorcin (a-CBDO) 0.01 0.031 (+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC) 0.01 0.036 11-Hydroxy-AB-Tetrahydrocannibinol (11-Hyd-AB-THC) 0.007 0.021 Cannabidiolic Acid (CBDA) 0.01 0.16 Cannabidgerol Acid (CBGA) 0.001 0.16 Cannabidgerol (CBG) 0.001 0.16 Cannabidiol (CBD) 0.01 0.16	NT NT ND ND ND ND ND NT	NT NT ND ND ND	NT NT ND ND	
(+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC) 0.012 0.036 11-Hydroxy-A8-Tetrahydrocannibinol (11-Hyd-Δ8-THC) 0.007 0.021 Cannabidiolic Acid (CBDA) 0.010 0.16 Cannabidgerol Acid (CBGA) 0.001 0.16 Cannabidgerol (CBG) 0.001 0.16 Cannabidiol (CBD) 0.001 0.16	NT ND ND ND ND ND NT	NT ND ND ND	NT NT ND ND	
1-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC) 0.007 0.021 Cannabidiolic Acid (CBDA) 0.001 0.16 Cannabigerol Acid (CBGA) 0.001 0.16 Cannabidiolic (CBG) 0.001 0.16 Cannabidiol (CBD) 0.001 0.16	NT ND ND ND ND NT	NT ND ND ND	NT ND ND	
Cannabidiolic Acid (CBDA) 0.001 0.16 Cannabidiolic Acid (CBGA) 0.001 0.16 Cannabigerol Acid (CBGA) 0.001 0.16 Cannabigerol (CBG) 0.001 0.16 Cannabidiol (CBD) 0.001 0.16	ND ND ND ND	ND ND ND	ND ND	
Cannabigerol Acid (CBGA) 0.001 0.16 Cannabigerol (CBG) 0.001 0.16 Cannabidiol (CBD) 0.001 0.16	ND ND ND NT	ND ND	ND	
Cannabigerol (CBG) 0.001 0.16 Cannabidiol (CBD) 0.001 0.16	ND ND NT	ND		
Cannabidiol (CBD) 0.001 0.16	ND NT		ND	A O
	NT	ND		DELIAO
1(S)_THD (e_THD) 0.013 0.041			ND	
0.015 0.041	NT	NT	NT	
1(R)-THD (r-THD) 0.025 0.075		NT	NT	
Tetrahydrocannabivarin (THCV) 0.001 0.16	ND	ND	ND	CONTRACTOR OF THE ACTION AND A
Δ8-tetrahydrocannabivarin (Δ8-THCV) 0.021 0.064	NT	NT	NT	
Cannabidihexol (CBDH) 0.005 0.16	NT	NT	NT	
Tetrahydrocannabutol (Δ9-THCB) 0.013 0.038	NT	NT	NT	
Cannabinol (CBN) 0.001 0.16	ND	ND	ND	
Cannabidiphorol (CBDP) 0.015 0.047	NT	NT	NT	
exo-THC (exo-THC) 0.005 0.16	ND	ND	ND	
Tetrahydrocannabinol (Δ9-THC) 0.003 0.16	UI	UI	UI	
۵.004 0.16 0.004 0.16	0.32	3.21	150.48	
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) 0.015 0.16	ND	ND	ND	
Hexahydrocannabinol (S Isomer) (9s-HHC) 0.017 0.16	ND	ND	ND	
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) 0.007 0.16	ND	ND	ND	
Hexahydrocannabinol (R Isomer) (9r-HHC) 0.016 0.16	ND	ND	ND	
Tetrahydrocannabinolic Acid (THCA) 0.001 0.16	ND	ND	ND	
Δ9-Tetrahydrocannabihexol (Δ9-THCH) 0.024 0.071	ND	ND	ND	
Cannabinol Acetate (CBNO) 0.014 0.043	NT	NT	NT	
۵۹-Tetrahydrocannabiphorol (۵۹-THCP) 0.017 0.16	ND	ND	ND	
	ND	ND	ND	
Cannabicitran (CBT) 0.005 0.16	NT	NT	NT	
Δ8-THC-O-acetate (Δ8-THCO) 0.076 0.16	ND	ND	ND	
9(S)-HHCP (s-HHCP) 0.031 0.094	NT	NT	NT	
Δ9-THC-O-acetate (Δ9-THCO) 0.066 0.16	ND	ND	ND	
9(R)-HHCP (r-HHCP) 0.026 0.079	NT	NT	NT	
9(S)-HHC-O-acetate (s-HHCO) 0.005 0.16	NT	NT	NT	
9(R)-HHC-O-acetate (r-HHCO) 0.008 0.025	NT	NT	NT	
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) 0.067 0.204	NT	NT	NT	
Δ9-THC methyl ether (Δ9-MeO-THC)	NT	NT	NT	
Cannabichromene (CBC) 0.002 0.16	ND	ND	ND	
Cannabidivarin (CBDV) 0.039 0.16	ND	ND	ND	
Total THC (THCα * 0.877 + Δ9THC)	UI	UI	UI	
Total THC + Δ8THC + Δ10THC (THca * 0.877 + Δ9THC + Δ8THC + Δ10THC)	0.32	3.21	150.48	
Total CBD (CBDa * 0.877 + CBD)	ND	ND	ND	
Total CBG (CBGa * 0.877 + CBG)	ND	ND	ND	
Total HHC (9r-HHC + 9s-HHC)	ND	ND	ND	
Total Cannabinoids Analyzed	0.32	3.21	150.48	

UI Unidentified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected AUQ Detected >ULQL Above upper limit of linearity >ULQL Above upper limit of linearity CFU/Q colony forming Units per 1 gram TNTC Too Numerous to Count



DCC license: C8-0000098-LIC DEA license: RP0611043 ISO/IEC 17025:2017 Acc. L17-427-1



Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Fri, 05 Aug 2022 11:30:25 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1 This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to plagnose, treat or prevent any disease. Results are only for samples and batches indicated. Aesults are reported on an 'as received' bass, unless indicated batches within a contrainty as writing and should not be used to plagnose, treat or prevent any disease. Results are only for samples and batches indicated. Aesults are reported the Pass/Foll submitted to the functional purposes. New York and the contrainty as writing are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Foll submitted in the Pass/Foll submitted in the Certificate of analysis. Measurement of uncertainty as writing are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Foll submitted in the Pass/Foll submitted in the certificate of analysis. Measurement of uncertainty is available upon required.